By Dr Wendy Winnall - PCFA Research TeamA recent prostate cancer study from Canada has received a lot of publicity. This study measured the risk of ...

For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

Repare Therapeutics shares jumped in premarket trading after the company agreed to sell its polymerase theta ATPase inhibitor to Gilead Sciences for up to $30 million. Shares were 18% higher at $2.57 ...

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Patient-led experimentation is increasingly influencing //conversations around cancer treatment options * ClinicalTrials are urgently needed before fenbendazole can be considere ...

Pancreatic cancer accounts for about 8% of all cancer deaths. Ben Sasse says he expects to be one of them. Here's what to ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.

A Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...